(Q28371011)

English

KRAS G12C

genetic variant

GLY12CYS
G12C
RS121913530

In more languages

default for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

human chromosome 12

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

25398285

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

25398285

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

positive therapeutic predictor for

selumetinib / docetaxel trihydrate combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

24 January 2019

https://civic.genome.wustl.edu/links/evidence/1142

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

selumetinib / dactolisib combination therapy

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

24 January 2019

https://civic.genome.wustl.edu/links/evidence/2212

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

negative therapeutic predictor for

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1216

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1216

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2257

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3973

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

cetuximab / chemotherapy combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3967

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

positive diagnostic predictor for

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/227

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

negative prognostic predictor for

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1217

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_004985.4:c.34G>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

NP_004976.2:p.Gly12Cys

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

NC_000012.11:g.25398285C>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

ENST00000256078.4:c.34G>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/78

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371011&oldid=2014798302"